Evaluation_NN of_IN an_DT In-House-Developed_NP Radioassay_NP Kit_NP for_IN Antibody_NP Detection_NP in_IN Cases_NPS of_IN Pulmonary_NP Tuberculosis_NP and_CC Tuberculous_NP Meningitis_NP A_DT radioassay_NN for_IN the_DT detection_NN of_IN antitubercular_JJ antibody_NN has_VBZ been_VBN developed_VBN ._SENT The_DT technique_NN involves_VBZ the_DT addition_NN of_IN 125I-labeled_JJ Mycobacterium_NN tuberculosis_NN antigen_NN as_IN a_DT tracer_NN ,_, diluted_VBN clinical_JJ sample_NN (_( serum_NN or_CC cerebrospinal_JJ fluid_NN [_SYM CSF_NP ]_SYM )_) ,_, and_CC heat-inactivated_JJ Staphylococcus_NP aureus_NN to_TO capture_VB the_DT antibody_NN ,_, incubation_NN for_IN 4_CD h_NN ,_, and_CC quantitation_NN of_IN the_DT amount_NN of_IN antibody_NN present_NN in_IN the_DT sample_NN ._SENT A_DT total_NN of_IN 330_CD serum_NN samples_NNS from_IN patients_NNS with_IN pulmonary_JJ tuberculosis_NN and_CC 138_CD control_NN serum_NN samples_NNS from_IN individuals_NNS who_WP were_VBD vaccinated_VBN with_IN M._NP bovis_NP BCG_NP and_CC from_IN patients_NNS with_IN pulmonary_JJ disorders_NNS of_IN nontubercular_JJ origin_NN were_VBD analyzed_VBN ._SENT Also_RB ,_, 26_CD CSF_NP samples_NNS from_IN patients_NNS with_IN tuberculous_JJ meningitis_NN and_CC 24_CD CSF_NP samples_NNS as_IN controls_NNS from_IN patients_NNS with_IN central_JJ nervous_JJ system_NN disorders_NNS of_IN nontuberculous_JJ origin_NN were_VBD analyzed_VBN ._SENT Sensitivities_NNS of_IN 80_CD and_CC 73_CD %_NN were_VBD observed_VBN for_IN patients_NNS with_IN pulmonary_JJ tuberculosis_NN and_CC tuberculous_JJ meningitis_NN ,_, respectively_RB ,_, and_CC specificities_NNS of_IN 90_CD and_CC 88_CD %_NN were_VBD seen_VBN for_IN the_DT two_CD groups_NNS of_IN patients_NNS ,_, respectively_RB ._SENT The_DT sensitivity_NN was_VBD lower_JJR ,_, however_RB ,_, for_IN human_JJ immunodeficiency_NN virus-infected_JJ patients_NNS coinfected_VBN with_IN M._NP tuberculosis_NN ._SENT The_DT control_NN population_NN could_MD be_VB differentiated_VBN from_IN the_DT patient_JJ population_NN ._SENT This_DT assay_NN is_VBZ rapid_JJ and_CC user_NN friendly_JJ and_CC ,_, with_IN its_PP$ good_JJ sensitivity_NN and_CC specificity_NN ,_, should_MD benefit_VB the_DT population_NN by_IN providing_VBG diagnoses_NNS early_JJ in_IN the_DT course_NN of_IN disease_NN and_CC ,_, hence_RB ,_, permit_VB the_DT early_JJ administration_NN of_IN appropriate_JJ chemotherapy_NN ._SENT Tuberculosis_NN ,_, caused_VBN by_IN Mycobacterium_NN tuberculosis_NN ,_, represents_VBZ a_DT major_JJ health_NN problem_NN worldwide_RB ._SENT It_PP is_VBZ estimated_VBN that_IN almost_RB one-third_JJ of_IN the_DT entire_JJ world_NN 's_POS population_NN is_VBZ exposed_VBN to_TO this_DT disease_NN ._SENT In_IN 1993_CD ,_, the_DT World_NP Health_NP Organization_NP declared_VBD tuberculosis_NN a_DT global_JJ emergency_NN and_CC estimated_VBD that_IN by_IN the_DT start_NN of_IN the_DT new_JJ millennium_NN there_EX would_MD be_VB more_JJR than_IN 1_CD billion_NNS newly_RB infected_VBN individuals_NNS and_CC more_JJR than_IN 17_CD million_CD deaths_NNS due_JJ to_TO this_DT disease_NN if_IN control_NN programs_NNS were_VBD not_RB implemented_VBN properly_RB ._SENT These_DT control_NN programs_NNS are_VBP dependent_JJ on_IN good_JJ tests_NNS for_IN early_JJ diagnosis_NN ,_, constant_JJ monitoring_NN of_IN disease_NN status_NN ,_, and_CC response_NN to_TO and_CC completion_NN of_IN treatment_NN ._SENT The_DT diagnosis_NN of_IN tuberculosis_NN has_VBZ never_RB been_VBN simple_JJ ,_, especially_RB in_IN children_NNS and_CC in_IN patients_NNS with_IN extrapulmonary_JJ tuberculosis_NN ,_, from_IN whom_WP clinical_JJ specimens_NNS for_IN microscopy_NN and_CC culture_NN are_VBP not_RB easily_RB obtained_VBN ._SENT Even_RB in_IN patients_NNS with_IN pulmonary_JJ tuberculosis_NN ,_, diagnosis_NN by_IN microscopy_NN is_VBZ rather_RB insensitive_JJ and_CC culture_NN is_VBZ time-consuming_JJ ._SENT Since_IN the_DT mid-1970s_CD radioimmunoassay_NN and_CC enzyme-linked_JJ immunosorbent_JJ assay_NN (_( ELISA_NP )_) techniques_NNS have_VBP been_VBN developed_VBN for_IN the_DT detection_NN of_IN M._NP tuberculosis_NN antigen_NN and_CC anti-M_NN ._SENT tuberculosis_NN antibody_NN from_IN clinical_JJ specimens_NNS ,_, and_CC these_DT assays_NNS have_VBP various_JJ degrees_NNS of_IN sensitivity_NN and_CC specificity_NN (_( ,_, ,_, ,_, 7_CD ,_, ,_, ,_, -_: ,_, ,_, -_: ,_, ,_, )_) ._SENT Almost_RB all_PDT the_DT assays_NNS developed_VBN at_IN the_DT Laboratory_NP Nuclear_NP Medicine_NP Section_NP of_IN the_DT Bhabha_NP Atomic_NP Research_NP Centre_NP require_VBP the_DT detection_NN of_IN both_DT antigen_NN and_CC antibody_NN from_IN clinical_JJ samples_NNS (_( ,_, ,_, -_: ,_, -_: )_) ._SENT With_IN the_DT incidence_NN of_IN tuberculosis_NN being_VBG on_IN the_DT rise_NN and_CC with_IN the_DT added_JJ risk_NN of_IN coinfection_NN with_IN human_JJ immunodeficiency_NN virus_NN (_( HIV_NP )_) ,_, the_DT need_NN at_IN this_DT time_NN is_VBZ for_IN a_DT test_NN with_IN good_JJ sensitivity_NN and_CC specificity_NN for_IN rapid_JJ and_CC early_JJ diagnosis_NN ._SENT With_IN this_DT as_IN the_DT aim_NN ,_, we_PP have_VBP modified_VBN the_DT antibody_NN test_NN and_CC describe_VB here_RB the_DT evaluation_NN of_IN a_DT single_JJ test_NN kit_NN for_IN the_DT diagnosis_NN of_IN tuberculosis_NN ._SENT Antigens_NNS ._SENT |_SYM M._NP tuberculosis_NN H37Rv_NP was_VBD grown_VBN in_IN Youman_NP 's_POS synthetic_JJ medium_NN for_IN 4_CD to_TO 6_CD weeks_NNS ._SENT Cultures_NNS were_VBD heat_NN inactivated_VBN by_IN autoclaving_VBG at_IN 120C_NP for_IN 20_CD min_NN ,_, followed_VBN by_IN sonication_NN for_IN extraction_NN of_IN antigen_NN from_IN the_DT cells_NNS ._SENT The_DT suspension_NN was_VBD ultracentrifuged_VBN at_IN 105,000_CD x_NN g_NN for_IN 90_CD min_NN ,_, and_CC the_DT supernatant_JJ was_VBD used_VBN as_IN the_DT source_NN of_IN antigen_NN ._SENT This_DT sonicate_NN antigen_NN was_VBD iodinated_VBN with_IN 125I_NP by_IN the_DT iodogen_NN method_NN ._SENT The_DT iodinated_JJ antigen_NN was_VBD purified_VBN from_IN free_JJ iodide_NN by_IN chromatography_NN on_IN a_DT Sepharose_NP 6B_JJ column_NN ._SENT The_DT immunoreactive_JJ peak_NN was_VBD used_VBN as_IN the_DT radioactive_JJ antigen_NN or_CC tracer_NN ._SENT Antibody_NN ._SENT |_SYM Rabbit_NP anti-M_NP ._SENT bovis_NP BCG_NP antibody_NN (_( M/S_NP Dakopatts_NP ,_, Copenhagen_NP ,_, Denmark_NP )_) was_VBD commercially_RB obtained_VBN and_CC was_VBD used_VBN for_IN the_DT preparation_NN of_IN quality_NN control_NN (_( QC_NP )_) samples_NNS ._SENT Solid_JJ phase_NN ._SENT |_SYM Staphylococcus_NP aureus_NN (_( strain_NN Cowan_NP I_NP )_) was_VBD used_VBN as_IN the_DT solid_JJ phase_NN ._SENT S._NP aureus_NN has_VBZ protein_NN A_DT on_IN its_PP$ surface_NN and_CC can_MD bind_VB to_TO immunoglobulins_NNS (_( immunoglobulin_NN G_NP [_SYM IgG_NP ]_SYM )_) efficiently_RB through_IN the_DT Fc_NP region_NN ._SENT The_DT S._NP aureus_NN cultures_NNS were_VBD grown_VBN in_IN nutrient_JJ medium_NN for_IN 3_CD to_TO 4_CD days_NNS ._SENT After_IN the_DT cells_NNS were_VBD harvested_VBN ,_, they_PP were_VBD heat_NN inactivated_VBN at_IN 80C_JJ for_IN 40_CD min_NN ._SENT A_DT 10_CD %_NN suspension_NN was_VBD made_VBN and_CC was_VBD used_VBN as_IN the_DT solid_JJ phase_NN ._SENT Assay_NN procedure_NN ._SENT |_SYM The_DT antibody_NN assay_NN developed_VBN is_VBZ a_DT single-step_VBP assay_NN ._SENT A_DT total_NN of_IN 0.1_CD ml_NN of_IN clinical_JJ sample_NN (_( a_DT serum_NN sample_NN diluted_VBN 1:25_CD or_CC a_DT neat_JJ cerebrospinal_JJ fluid_NN [_SYM CSF_NP ]_SYM sample_NN )_) whose_WP$ antibody_NN levels_NNS are_VBP to_TO be_VB determined_VBN was_VBD incubated_VBN with_IN 0.1_CD ml_NN of_IN an_DT S._NP aureus_NN suspension_NN diluted_VBN 1:3_CD and_CC 0.3_CD ml_NN of_IN 125I-labeled_JJ M._NP tuberculosis_NN antigen_NN ._SENT Assay_NN control_NN samples_NNS and_CC QC_NN samples_NNS were_VBD also_RB treated_VBN in_IN the_DT same_JJ way_NN as_IN the_DT patient_JJ samples_NNS ._SENT The_DT reaction_NN mixture_NN was_VBD incubated_VBN for_IN 4_CD h_NN at_IN room_NN temperature_NN with_IN constant_JJ shaking_VBG ._SENT Subsequently_RB ,_, 2_CD ml_NN of_IN 0.02_CD M_NP barbitone_NN buffer_NN (_( pH_NN 7.6_CD )_) was_VBD added_VBN ,_, and_CC the_DT entire_JJ mixture_NN was_VBD centrifuged_VBN at_IN 2,000_CD x_NN g_NN for_IN 40_CD min_NN ._SENT The_DT supernatant_JJ was_VBD aspirated_VBN ,_, the_DT pellet_NN was_VBD counted_VBN in_IN a_DT gamma_NN counter_NN ,_, and_CC the_DT antibody_NN concentration_NN in_IN the_DT samples_NNS was_VBD determined_VBN by_IN calculating_VBG the_DT ratio_NN as_RB described_VBD in_IN the_DT Results_NNS ._SENT Determination_NN of_IN assay_NN cutoff_NN and_CC assay_NN control_NN samples_NNS ._SENT |_SYM In_IN order_NN to_TO determine_VB a_DT cutoff_NN limit_NN for_IN negativity_NN above_IN which_WDT the_DT clinical_JJ samples_NNS could_MD be_VB classified_VBN as_IN positive_JJ ,_, a_DT standard_JJ curve_NN was_VBD constructed_VBN by_IN using_VBG anti-BCG_NP IgG_NP as_IN the_DT standard_NN ,_, with_IN concentrations_NNS ranging_VBG from_IN 5_CD to_TO 200_CD mug/dl_NN ,_, as_RB shown_VBN in_IN Fig._NN ._SENT The_DT assay_NN was_VBD performed_VBN as_IN described_VBN above_IN with_IN 77_CD control_NN serum_NN samples_NNS ._SENT These_DT samples_NNS were_VBD taken_VBN from_IN healthy_JJ individuals_NNS and_CC patients_NNS with_IN pulmonary_JJ infections_NNS of_IN nontubercular_JJ nature_NN ._SENT Antibody_NN levels_NNS were_VBD quantitated_VBN by_IN referring_VBG to_TO the_DT standard_JJ curve_NN and_CC are_VBP expressed_VBN as_IN micrograms_NNS per_IN deciliter_NN ._SENT The_DT values_NNS obtained_VBN were_VBD calculated_VBN for_IN the_DT upper_JJ limit_NN of_IN negativity_NN as_IN the_DT mean_NN +_SYM 3_CD standard_JJ deviations_NNS (_( SDs_NP )_) ,_, which_WDT was_VBD found_VBN to_TO be_VB 25_CD mug_NN of_IN IgG_NP per_IN dl_NP ,_, as_RB shown_VBN in_IN Fig._NN ._SENT With_IN this_DT as_IN the_DT basis_NN ,_, two_CD assay_NN control_NN samples_NNS were_VBD included_VBN in_IN the_DT kit_NN and_CC for_IN calculation_NN purposes_NNS ._SENT Control_NP C1_NP ,_, which_WDT represented_VBD nonspecific_JJ binding_NN ,_, was_VBD the_DT assay_NN buffer_NN with_IN no_DT antibody_NN ,_, and_CC control_NN C2_NN represented_VBD a_DT concentration_NN of_IN 25_CD mug_NN of_IN anti-BCG_NP IgG_NP per_IN dl_NN in_IN the_DT same_JJ assay_NN buffer_NN ._SENT Stability_NN of_IN the_DT kit_NN ._SENT |_SYM The_DT stability_NN of_IN the_DT kit_NN was_VBD determined_VBN for_IN a_DT period_NN of_IN 7_CD weeks_NNS both_CC at_IN room_NN temperature_NN (_( RT_NP )_) and_CC at_IN 4C_JJ ._SENT In_IN this_DT case_NN ,_, the_DT kits_NNS were_VBD kept_VBN at_IN RT_NP and_CC at_IN 4C_NP and_CC were_VBD evaluated_VBN at_IN 0_CD ,_, 1_CD ,_, 2_CD ,_, 3_CD ,_, 4_CD ,_, and_CC 7_CD weeks_NNS ._SENT QC_NP samples_NNS Q1_NP and_CC Q2_NP were_VBD also_RB included_VBN to_TO determine_VB the_DT reproducibility_NN of_IN the_DT assay_NN ._SENT Sample_NN selection_NN ._SENT (_( i_NP )_) Pulmonary_NP tuberculosis_NN ._SENT |_SYM Three_CD hundred_CD and_CC thirty_CD blood_NN samples_NNS were_VBD collected_VBN from_IN patients_NNS attending_VBG a_DT tuberculosis_NN clinic_NN ._SENT The_DT patients_NNS had_VBD pulmonary_JJ tuberculosis_NN at_IN various_JJ stages_NNS of_IN the_DT disease_NN and_CC were_VBD at_IN various_JJ stages_NNS of_IN treatment_NN ._SENT For_IN all_DT patients_NNS ,_, the_DT diagnosis_NN of_IN tuberculosis_NN was_VBD made_VBN on_IN the_DT basis_NN of_IN the_DT following_VBG criteria_NNS ,_, determined_VBN by_IN taking_VBG a_DT detailed_JJ history_NN :_: (_( i_NP )_) presenting_VBG clinical_JJ signs_NNS and_CC symptoms_NNS such_JJ as_IN cough_NN and_CC fever_NN ;_: (_( ii_NP )_) BCG_NP vaccination_NN status_NN ,_, past_JJ history_NN of_IN tuberculosis_NN ,_, or_CC presence_NN of_IN a_DT close_JJ contact_NN with_IN tuberculosis_NN ;_: (_( iii_NP )_) routine_JJ laboratory_NN tests_NNS which_WDT included_VBD assay_NN of_IN sputum_NN for_IN acid-fast_JJ bacilli_NNS (_( AFB_NP )_) ,_, culture_NN of_IN sputum_NN ,_, skin_NN test_NN ,_, and_CC chest_NN X_NN ray_NN ;_: and_CC (_( iv_NN )_) response_NN to_TO antituberculosis_NN treatment_NN ,_, as_RB against_IN specific_JJ treatment_NN for_IN chronic_JJ obstructive_JJ pulmonary_JJ disease_NN (_( COPD_NN )_) and_CC asthma_NN ._SENT On_IN the_DT basis_NN of_IN the_DT criteria_NNS described_VBD above_RB ,_, the_DT patients_NNS were_VBD diagnosed_VBN as_IN having_VBG tuberculosis_NN and_CC classified_VBN into_IN the_DT groups_NNS described_VBD below_RB ._SENT Group_NP I_NP comprised_VBD 86_CD patients_NNS who_WP were_VBD positive_JJ by_IN both_DT smear_NN for_IN AFB_NP and_CC culture_NN ._SENT Of_IN these_DT ,_, 20_CD patients_NNS had_VBD fresh_JJ cases_NNS of_IN tuberculosis_NN ,_, 14_CD had_VBD been_VBN treated_VBN for_IN tuberculosis_NN with_IN antituberculosis_NN drugs_NNS for_IN less_JJR than_IN 6_CD months_NNS ,_, 11_CD had_VBD been_VBN treated_VBN for_IN 6_CD months_NNS to_TO 1_CD year_NN ,_, and_CC 33_CD had_VBD been_VBN treated_VBN for_IN more_JJR than_IN 1_CD year_NN ;_: data_NNS on_IN the_DT treatment_NN given_VBN were_VBD not_RB available_JJ for_IN 8_CD patients_NNS ._SENT Group_NP II_NP comprised_VBD 126_CD patients_NNS who_WP were_VBD negative_JJ by_IN smear_NN for_IN AFB_NP but_CC positive_JJ by_IN culture_NN ._SENT In_IN this_DT group_NN ,_, 23_CD patients_NNS had_VBD fresh_JJ cases_NNS of_IN tuberculosis_NN ,_, 15_CD had_VBD been_VBN treated_VBN for_IN less_JJR than_IN 6_CD months_NNS ,_, 16_CD had_VBD been_VBN treated_VBN for_IN 6_CD months_NNS to_TO 1_CD year_NN ,_, and_CC 57_CD had_VBD been_VBN treated_VBN for_IN more_JJR than_IN a_DT year_NN ;_: data_NNS on_IN the_DT type_NN of_IN treatment_NN given_VBN were_VBD not_RB available_JJ for_IN 15_CD patients_NNS ._SENT Group_NP III_NP comprised_VBD 118_CD patients_NNS who_WP were_VBD negative_JJ by_IN both_DT smear_NN for_IN AFB_NP and_CC culture_NN ._SENT However_RB ,_, 99_CD of_IN these_DT patients_NNS had_VBD previously_RB received_VBN a_DT diagnosis_NN of_IN tuberculosis_NN on_IN the_DT basis_NN of_IN a_DT positive_JJ smear_NN for_IN AFB_NP and_CC culture_NN and_CC were_VBD receiving_VBG antituberculosis_NN treatment_NN ._SENT Nine_CD patients_NNS had_VBD been_VBN treated_VBN with_IN antituberculosis_NN drugs_NNS for_IN less_JJR than_IN 6_CD months_NNS ,_, 14_CD had_VBD been_VBN treated_VBN for_IN 6_CD months_NNS to_TO 1_CD year_NN ,_, and_CC 45_CD had_VBD been_VBN treated_VBN for_IN more_JJR than_IN 1_CD year_NN ;_: data_NNS on_IN the_DT type_NN of_IN treatment_NN given_VBN were_VBD not_RB available_JJ for_IN 31_CD patients_NNS ._SENT Only_RB 19_CD patients_NNS in_IN this_DT group_NN had_VBD fresh_JJ cases_NNS of_IN tuberculosis_NN ,_, and_CC diagnosis_NN was_VBD made_VBN on_IN the_DT basis_NN of_IN a_DT combination_NN of_IN tests_NNS and_CC criteria_NNS such_JJ as_IN X_NP ray_NN ,_, skin_NN test_NN ,_, and_CC presence_NN of_IN a_DT contact_NN ._SENT Further_JJR analysis_NN indicated_VBD that_IN 33_CD of_IN the_DT 330_CD tuberculosis_NN patients_NNS were_VBD HIV_NP positive_NN ._SENT Of_IN these_DT ,_, 7_CD patients_NNS were_VBD in_IN group_NN I_PP ,_, 16_CD were_VBD in_IN group_NN II_NP ,_, and_CC 10_CD were_VBD in_IN group_NN III_NP ._SENT The_DT control_NN group_NN comprised_VBD 138_CD individuals_NNS between_IN the_DT ages_NNS of_IN 21_CD and_CC 50_CD years_NNS who_WP had_VBD no_DT prior_JJ history_NN of_IN tuberculosis_NN but_CC who_WP had_VBD all_RB been_VBN vaccinated_VBN with_IN BCG_NP ._SENT Thirty-one_JJ of_IN these_DT were_VBD healthy_JJ volunteers_NNS ,_, 75_CD had_VBD bronchitis_NN leading_VBG to_TO COPD_NNS ,_, and_CC 28_CD were_VBD asthma_NN patients_NNS ._SENT Diagnosis_NN of_IN COPD_NN and_CC asthma_NN was_VBD done_VBN on_IN the_DT basis_NN of_IN the_DT criteria_NNS given_VBN earlier_RBR ,_, such_JJ as_IN X_NP ray_NN ,_, sputum_NN cultures_NNS ,_, clinical_JJ presentation_NN ,_, and_CC response_NN to_TO antibacterial_NN treatment_NN ._SENT COPD_NN patients_NNS were_VBD treated_VBN with_IN aminophylline_NN and_CC theophylline_NN ,_, and_CC asthma_NN patients_NNS were_VBD treated_VBN with_IN bronchodilators_NNS ._SENT (_( ii_NP )_) Extrapulmonary_NP tuberculosis_NN ._SENT |_SYM Fifty_NP CSF_NP samples_NNS were_VBD collected_VBN from_IN individuals_NNS with_IN signs_NNS and_CC symptoms_NNS of_IN meningitis_NN and_CC other_JJ neurological_JJ disorders_NNS ._SENT Of_IN these_DT ,_, 26_CD were_VBD diagnosed_VBN as_IN having_VBG tuberculous_JJ meningitis_NN on_IN the_DT basis_NN of_IN the_DT results_NNS of_IN clinical_JJ and_CC biochemical_JJ investigations_NNS ._SENT Twenty-four_NP of_IN the_DT patients_NNS had_VBD central_JJ nervous_JJ system_NN (_( CNS_NP )_) disorders_NNS of_IN nontuberculous_JJ origin_NN ._SENT FIG._NN 1_CD ._SENT |_SYM (_( a_DT )_) Standard_NP curve_NN for_IN the_DT antibody_NN assay_NN ;_: (_( b_LS )_) determination_NN of_IN the_DT cutoff_NN value_NN ._SENT (_( a_DT )_) Standard_NP curve_NN for_IN the_DT antibody_NN assay_NN ;_: (_( b_LS )_) determination_NN of_IN the_DT cutoff_NN value_NN ._SENT Calculation_NN ._SENT |_SYM The_DT amount_NN of_IN antibody_NN in_IN the_DT clinical_JJ samples_NNS was_VBD determined_VBN by_IN using_VBG the_DT two_CD assay_NN controls_NNS (_( C1_NP and_CC C2_NP )_) included_VBD in_IN the_DT kit_NN ._SENT Control_NP C1_NP represented_VBD nonspecific_JJ binding_NN with_IN no_DT antibody_NN ,_, and_CC control_NN C2_NN represented_VBD an_DT anti-BCG_NP IgG_NP concentration_NN of_IN 25_CD mug/dl_NN ._SENT The_DT ratio_NN X_NN (_( as_IN a_DT percentage_NN )_) was_VBD calculated_VBN by_IN using_VBG the_DT counts_NNS in_IN C1_NP ,_, C2_NP ,_, and_CC the_DT unknown_NN ,_, as_RB follows_VBZ :_: [_SYM (_( counts_NNS in_IN unknown_JJ -_: counts_NNS in_IN control_NN C1)/(counts_NNS in_IN control_NN C2_NN -_: counts_NNS in_IN control_NN C1_NP )_) ]_SYM x_SYM 100_CD ._SENT Samples_NNS that_WDT gave_VBD values_NNS of_IN more_JJR than_IN 100_CD were_VBD considered_VBN positive_JJ ._SENT Stability_NN of_IN the_DT kit_NN ._SENT |_SYM In_IN order_NN to_TO ascertain_VB the_DT stability_NN of_IN the_DT kit_NN ,_, the_DT reproducibilities_NNS of_IN values_NNS for_IN the_DT QC_NP samples_NNS in_IN the_DT kit_NN were_VBD determined_VBN ._SENT The_DT expected_VBN value_NN of_IN the_DT ratio_NN for_IN QC_NP Q1_NP was_VBD 200_CD ,_, and_CC the_DT mean_JJ observed_JJ values_NNS over_IN a_DT period_NN of_IN 7_CD weeks_NNS were_VBD 198_CD and_CC 205_CD at_IN RT_NP and_CC 4C_JJ ,_, respectively_RB ._SENT The_DT SD_NN and_CC percent_NN coefficient_NN of_IN variation_NN (_( CV_NP )_) were_VBD 22.8_CD and_CC 11.5_CD %_NN ,_, respectively_RB ,_, at_IN RT_NP and_CC 18.7_CD and_CC 9.1_CD %_NN ,_, respectively_RB ,_, at_IN 4C_JJ ._SENT The_DT expected_VBN value_NN of_IN the_DT ratio_NN for_IN the_DT second_JJ QC_NP ,_, Q2_NP ,_, was_VBD 400_CD ,_, with_IN mean_JJ values_NNS of_IN 344_CD and_CC 355_CD at_IN RT_NP and_CC 4C_JJ ,_, respectively_RB ._SENT The_DT SD_NP and_CC CV_NP were_VBD 50.8_CD and_CC 14.7_CD %_NN ,_, respectively_RB ,_, at_IN RT_NP and_CC 41.9_CD and_CC 11.8_CD %_NN ,_, respectively_RB ,_, at_IN 4C_JJ ._SENT These_DT CVs_NP were_VBD within_IN the_DT statistically_RB acceptable_JJ range_NN for_IN interassay_NN variability_NN ._SENT These_DT results_NNS are_VBP represented_VBN graphically_RB in_IN Fig._NN Pulmonary_JJ tuberculosis_NN ._SENT |_SYM Table_NP presents_VBZ the_DT antibody_NN responses_NNS in_IN patients_NNS with_IN pulmonary_JJ tuberculosis_NN with_IN respect_NN to_TO the_DT period_NN of_IN treatment_NN given_VBN ,_, and_CC Table_NP presents_VBZ the_DT antibody_NN responses_NNS in_IN patients_NNS with_IN HIV_NP and_CC M._NP tuberculosis_NN coinfection_NN ._SENT It_PP was_VBD observed_VBN that_IN 14_CD of_IN the_DT 138_CD control_NN samples_NNS had_VBD antibody_NN levels_NNS above_IN the_DT ratio_NN cutoff_NN value_NN of_IN 100_CD ,_, contributing_VBG to_TO a_DT rate_NN of_IN nonspecific_JJ detection_NN of_IN 10_CD %_NN and_CC a_DT specificity_NN of_IN 90_CD %_NN ._SENT Group_NP I_NP comprised_VBD 86_CD patients_NNS who_WP were_VBD positive_JJ by_IN both_DT smear_NN and_CC culture_NN and_CC had_VBD 69_CD patients_NNS who_WP had_VBD high_JJ antibody_NN ratios_NNS ,_, giving_VBG the_DT test_NN a_DT sensitivity_NN of_IN 80.2_CD %_NN and_CC a_DT positive_JJ predictive_JJ value_NN of_IN 83.1_CD %_NN ._SENT Of_IN the_DT 7_CD HIV-positive_JJ patients_NNS in_IN this_DT group_NN ,_, 4_CD patients_NNS had_VBD high_JJ titers_NNS of_IN antitubercular_JJ antibody_NN ._SENT Group_NP II_NP had_VBD 126_CD patients_NNS who_WP were_VBD negative_JJ by_IN smear_NN but_CC positive_JJ by_IN culture_NN ._SENT Of_IN these_DT ,_, 92_CD were_VBD positive_JJ for_IN antibody_NN ,_, giving_VBG the_DT test_NN a_DT sensitivity_NN of_IN 73_CD %_NN and_CC a_DT positive_JJ predictive_JJ value_NN of_IN 86.8_CD %_NN ._SENT Six_CD of_IN the_DT 16_CD patients_NNS in_IN this_DT group_NN were_VBD positive_JJ for_IN both_DT HIV_NP and_CC M._NP tuberculosis_NN and_CC had_VBD high_JJ titers_NNS of_IN antibodies_NNS against_IN M._NP tuberculosis_NN ._SENT Group_NP III_NP comprised_VBD 118_CD patients_NNS who_WP were_VBD negative_JJ by_IN both_DT smear_NN and_CC culture_NN and_CC had_VBD 71_CD patients_NNS with_IN high_JJ antibody_NN titers_NNS ,_, giving_VBG the_DT test_NN a_DT sensitivity_NN of_IN 60.2_CD %_NN and_CC positive_JJ predictive_JJ value_NN of_IN 83.5_CD %_NN ._SENT Three_CD of_IN the_DT 10_CD HIV-positive_JJ patients_NNS in_IN this_DT group_NN also_RB had_VBD high_JJ antibody_NN levels_NNS ._SENT The_DT detailed_JJ analysis_NN of_IN each_DT subgroup_NN is_VBZ presented_VBN in_IN Tables_NP and_CC 2_CD ._SENT Figure_NN provides_VBZ a_DT graphical_JJ representation_NN of_IN the_DT response_NN ratios_NNS for_IN the_DT different_JJ groups_NNS of_IN patients_NNS with_IN pulmonary_JJ tuberculosis_NN ._SENT Compared_VBN to_TO the_DT antitubercular_JJ antibody_NN levels_NNS in_IN the_DT control_NN group_NN ,_, the_DT patient_JJ groups_NNS had_VBD high_JJ levels_NNS of_IN antitubercular_JJ antibody_NN ._SENT The_DT patient_JJ population_NN was_VBD further_RBR classified_VBN as_IN those_DT who_WP had_VBD received_VBN antituberculous_JJ treatment_NN at_IN the_DT time_NN of_IN sample_NN collection_NN and_CC those_DT who_WP had_VBD not_RB received_VBN any_DT treatment_NN at_IN the_DT time_NN of_IN sample_NN collection_NN (_( fresh_JJ cases_NNS )_) ._SENT The_DT test_NN showed_VBD a_DT sensitivity_NN of_IN 62.9_CD %_NN and_CC a_DT positive_JJ predictive_JJ value_NN of_IN 73.6_CD %_NN for_IN the_DT patients_NNS with_IN fresh_JJ cases_NNS ._SENT For_IN the_DT treated_VBN patients_NNS ,_, the_DT sensitivity_NN was_VBD 72_CD %_NN and_CC the_DT positive_JJ predictive_JJ value_NN was_VBD 93.2_CD %_NN ,_, as_RB depicted_VBN in_IN Table_NP ._SENT Extrapulmonary_JJ tuberculosis_NN ._SENT |_SYM Table_NP represents_VBZ the_DT percent_NN positivity_NN of_IN antibody_NN detection_NN in_IN patients_NNS with_IN tuberculous_JJ meningitis_NN ._SENT Of_IN the_DT 26_CD patients_NNS with_IN clinically_RB proven_VBN tuberculous_JJ meningitis_NN ,_, 19_CD had_VBD high_JJ antibody_NN levels_NNS by_IN this_DT test_NN ,_, giving_VBG a_DT sensitivity_NN of_IN 73_CD %_NN ._SENT A_DT false-positivity_NN rate_NN of_IN 12_CD %_NN was_VBD observed_VBN for_IN the_DT control_NN group_NN ,_, giving_VBG a_DT specificity_NN of_IN 88_CD %_NN and_CC a_DT positive_JJ predictive_JJ value_NN of_IN 91_CD %_NN ._SENT Figure_NN is_VBZ a_DT graphical_JJ representation_NN of_IN the_DT antibody_NN response_NN ratios_NNS for_IN patients_NNS with_IN CNS_NP disorders_NNS of_IN tuberculous_JJ and_CC nontuberculous_JJ origin_NN ._SENT FIG._NN 2_CD ._SENT |_SYM Stability_NP of_IN the_DT kit_NN at_IN RT_NP (_( a_DT )_) and_CC at_IN 4C_JJ (_( b_LS )_) ._SENT Stability_NN of_IN the_DT kit_NN at_IN RT_NP (_( a_DT )_) and_CC at_IN 4C_JJ (_( b_LS )_) ._SENT *_SYM ,_, C1_JJ ;_: ,_, C2_NP ;_: ,_, QC1_NP ;_: ,_, QC2_NP ._SENT FIG._NN 3_CD ._SENT |_SYM Antibody_NN levels_NNS in_IN patients_NNS with_IN pulmonary_JJ tuberculosis_NN ._SENT Antibody_NN levels_NNS in_IN patients_NNS with_IN pulmonary_JJ tuberculosis_NN ._SENT ,_, group_VB I_PP ;_: ,_, group_NN II_NP ;_: ,_, group_NN III_NP ;_: *_SYM ,_, group_NN IV_NP (_( controls_NNS )_) ._SENT FIG._NN 4_CD ._SENT |_SYM Antibody_NN levels_NNS in_IN patients_NNS with_IN tuberculous_JJ meningitis_NN ._SENT Antibody_NN levels_NNS in_IN patients_NNS with_IN tuberculous_JJ meningitis_NN ._SENT ,_, patients_NNS with_IN tuberculous_JJ meningitis_NN ;_: ,_, controls_NNS (_( patients_NNS with_IN CNS_NP disorders_NNS of_IN a_DT nontubercular_JJ nature_NN )_) ._SENT TABLE_NN 1_CD |_SYM Antibody_JJ response_NN in_IN pulmonary_JJ tuberculosis_NN TABLE_NP 2_CD |_SYM Antibody_NN responses_NNS in_IN patients_NNS with_IN HIV_NP and_CC M._NP tuberculosis_NN coinfection_NN TABLE_NP 3_CD |_SYM Predictive_JJ values_NNS for_IN treated_VBN and_CC nontreated_JJ patients_NNS TABLE_NP 4_CD |_SYM Antibody_JJ response_NN in_IN patients_NNS with_IN tuberculous_JJ meningitis_NN The_DT need_NN for_IN a_DT serological_JJ test_NN for_IN the_DT diagnosis_NN of_IN tuberculosis_NN is_VBZ emphasized_VBN on_IN the_DT grounds_NNS of_IN potential_JJ benefits_NNS for_IN rapid_JJ and_CC differential_JJ diagnosis_NN ,_, particularly_RB in_IN culture-_NN and/or_CC smear-negative_JJ patients_NNS ._SENT During_IN bacterial_JJ diseases_NNS like_IN tuberculosis_NN ,_, the_DT immune_JJ response_NN leads_VBZ to_TO a_DT rise_NN in_IN the_DT titers_NNS of_IN antibodies_NNS against_IN different_JJ antigenic_JJ determinants_NNS of_IN the_DT organisms_NNS ,_, and_CC hence_RB ,_, the_DT specific_JJ antibodies_NNS present_NN may_MD range_VB from_IN those_DT that_WDT are_VBP species_NN specific_JJ to_TO those_DT that_WDT share_VBP certain_JJ common_JJ antigenic_JJ determinants_NNS with_IN the_DT causative_JJ organisms_NNS ._SENT The_DT antibody_NN response_NN in_IN tuberculosis_NN has_VBZ been_VBN studied_VBN for_IN a_DT long_JJ time_NN (_( ,_, ,_, ,_, ,_, 13_CD ,_, ,_, -_: ,_, ,_, -_: ,_, ,_, )_) ._SENT Although_IN one_CD of_IN the_DT major_JJ drawbacks_NNS ,_, especially_RB in_IN serological_JJ tests_NNS ,_, is_VBZ the_DT persistence_NN of_IN antibodies_NNS even_RB after_IN effective_JJ treatment_NN ,_, measurement_NN of_IN the_DT antibody_NN response_NN to_TO 38-kDa_JJ antigen_NN has_VBZ been_VBN found_VBN to_TO be_VB useful_JJ in_IN assessing_VBG the_DT effectiveness_NN of_IN treatment_NN in_IN patients_NNS with_IN tuberculous_JJ meningitis_NN ._SENT A_DT radioimmunoassay_NN for_IN the_DT detection_NN of_IN M._NP tuberculosis_NN antigen_NN and_CC anti-M_NN ._SENT tuberculosis_NN antibodies_NNS developed_VBN at_IN the_DT Laboratory_NP Nuclear_NP Medicine_NP Section_NP of_IN the_DT Bhabha_NP Atomic_NP Research_NP Centre_NP has_VBZ been_VBN tested_VBN with_IN samples_NNS from_IN patients_NNS with_IN various_JJ clinical_JJ manifestations_NNS of_IN tuberculosis_NN (_( ,_, ,_, ,_, ,_, -_: )_) ._SENT It_PP was_VBD demonstrated_VBN that_DT detection_NN of_IN antigen_NN and_CC antibody_NN gave_VBD a_DT good_JJ sensitivity_NN and_CC specificity_NN for_IN diagnosis_NN ._SENT It_PP was_VBD also_RB shown_VBN that_IN antibody_NN detection_NN alone_RB could_MD be_VB useful_JJ for_IN the_DT diagnosis_NN of_IN tuberculous_JJ meningitis_NN ._SENT Antigen_NN and_CC antibody_NN detection_NN in_IN patients_NNS with_IN pulmonary_JJ tuberculosis_NN was_VBD done_VBN from_IN immune_JJ complexes_NNS ,_, not_RB serum_NN ._SENT In_IN this_DT particular_JJ study_NN ,_, antibody_NN levels_NNS in_IN serum_NN samples_NNS from_IN patients_NNS with_IN pulmonary_JJ tuberculosis_NN were_VBD measured_VBN ._SENT The_DT aim_NN of_IN the_DT present_JJ work_NN was_VBD to_TO make_VB the_DT test_NN user_NN friendly_JJ and_CC evaluate_VB detection_NN of_IN antibody_NN from_IN serum_NN rather_RB than_IN immune_JJ complexes_NNS in_IN the_DT case_NN of_IN pulmonary_JJ tuberculosis_NN ._SENT The_DT modified_JJ antibody_NN assay_NN described_VBD here_RB is_VBZ simple_JJ and_CC rapid_JJ and_CC involves_VBZ the_DT addition_NN and_CC incubation_NN of_IN all_DT reagents_NNS together_RB for_IN 4_CD h_NN at_IN room_NN temperature_NN with_IN a_DT final_JJ centrifugation_NN step_NN ._SENT This_DT not_RB only_RB reduces_VBZ the_DT pipetting_VBG errors_NNS and_CC the_DT number_NN of_IN centrifugation_NN steps_NNS required_VBN but_CC also_RB reduces_VBZ the_DT incubation_NN time_NN ,_, facilitating_VBG early_JJ diagnosis_NN and_CC hence_RB the_DT early_JJ institution_NN of_IN treatment_NN ._SENT The_DT most_RBS significant_JJ aspect_NN of_IN this_DT test_NN was_VBD that_IN it_PP was_VBD useful_JJ for_IN the_DT diagnosis_NN of_IN tuberculosis_NN in_IN those_DT patients_NNS for_IN whom_WP the_DT rapid_JJ test_NN for_IN AFB_NP was_VBD negative_JJ ,_, which_WDT included_VBD patients_NNS from_IN group_NN II_NP and_CC group_NN III_NP ._SENT Although_IN a_DT false-positivity_NN rate_NN of_IN 10_CD %_NN was_VBD observed_VBN for_IN the_DT control_NN population_NN ,_, this_DT was_VBD acceptable_JJ ,_, as_IN India_NP is_VBZ an_DT area_NN with_IN a_DT high_JJ prevalence_NN of_IN tuberculosis_NN and_CC the_DT entire_JJ population_NN is_VBZ vaccinated_VBN with_IN BCG_NP ._SENT Early_JJ diagnosis_NN and_CC early_JJ treatment_NN of_IN tuberculosis_NN in_IN patients_NNS coinfected_VBN with_IN HIV_NP are_VBP mandatory_JJ ,_, as_IN delayed_VBN therapy_NN results_NNS in_IN increased_VBN rates_NNS of_IN mortality_NN ._SENT In_IN the_DT present_JJ study_NN ,_, in_IN the_DT case_NN of_IN patients_NNS coinfected_VBN with_IN M._NP tuberculosis_NN and_CC HIV_NP ,_, antibodies_NNS against_IN M._NP tuberculosis_NN persisted_VBD even_RB after_IN antituberculosis_NN treatment_NN ._SENT However_RB ,_, the_DT percent_NN positivity_NN of_IN antibody_NN detection_NN for_IN the_DT HIV-infected_JJ tuberculous_JJ patient_NN population_NN is_VBZ lower_JJR than_IN that_DT for_IN the_DT entire_JJ tuberculous_JJ patient_NN population_NN (_( Table_NP and_CC Table_NP )_) ._SENT These_DT findings_NNS were_VBD similar_JJ to_TO those_DT presented_VBN in_IN other_JJ reports_NNS ,_, in_IN which_WDT the_DT sensitivity_NN dropped_VBD from_IN 62_CD %_NN for_IN non-HIV-infected_NP tuberculous_JJ patients_NNS to_TO 28_CD %_NN for_IN HIV-infected_JJ tuberculous_JJ patients_NNS ._SENT It_PP has_VBZ been_VBN reported_VBN that_IN no_DT antibody_NN is_VBZ detected_VBN by_IN an_DT immunochromatographic_JJ test_NN (_( ICT_NP )_) for_IN tuberculosis_NN in_IN any_DT of_IN the_DT serum_NN samples_NNS of_IN HIV-infected_JJ patients_NNS coinfected_VBN with_IN M._NP tuberculosis_NN or_CC mycobacteria_NNS other_JJ than_IN M._NP tuberculosis_NN ._SENT Evaluation_NN of_IN the_DT Mycodot_NP immunodiagnostic_JJ test_NN for_IN the_DT diagnosis_NN of_IN tuberculosis_NN ,_, which_WDT detects_VBZ antibodies_NNS to_TO lipoarabinomannan_JJ antigen_NN ,_, showed_VBD that_IN it_PP has_VBZ very_RB good_JJ specificity_NN ._SENT The_DT sensitivity_NN of_IN detection_NN for_IN HIV-negative_JJ tuberculous_JJ patients_NNS was_VBD 56_CD %_NN and_CC much_RB lower_JJR ,_, as_RB low_JJ as_IN 25_CD %_NN ,_, for_IN HIV-positive_JJ patients_NNS ._SENT In_IN general_JJ ,_, serological_JJ assays_NNS have_VBP high_JJ negative_JJ values_NNS for_IN HIV-positive_JJ individuals_NNS ,_, low_JJ sensitivities_NNS ,_, and_CC low_JJ negative_JJ predictive_JJ values_NNS ,_, which_WDT markedly_RB decreases_VBZ their_PP$ utility_NN in_IN populations_NNS in_IN which_WDT HIV_NP infection_NN is_VBZ prevalent_JJ ._SENT Diagnosis_NN of_IN tuberculous_JJ meningitis_NN has_VBZ always_RB been_VBN a_DT challenge_NN ,_, especially_RB in_IN children_NNS ._SENT Data_NNS from_IN a_DT previous_JJ study_NN in_IN which_WDT the_DT 38-kDa_JJ antigen_NN in_IN the_DT ELISA_NP system_NN was_VBD used_VBN for_IN the_DT detection_NN of_IN antibodies_NNS in_IN CSF_NP samples_NNS showed_VBD sensitivities_NNS of_IN 60_CD %_NN for_IN patients_NNS proven_VBN to_TO have_VB tuberculosis_NN postmortem_NN ,_, 80_CD %_NN for_IN patients_NNS with_IN culture-proven_JJ tuberculous_JJ meningitis_NN ,_, and_CC 62.5_CD %_NN for_IN patients_NNS with_IN clinically_RB proven_VBN tuberculous_JJ meningitis_NN ._SENT The_DT sensitivity_NN in_IN that_DT study_NN was_VBD superior_JJ to_TO those_DT reported_VBD elsewhere_RB ._SENT Use_NN of_IN the_DT 19-kDa_NP antigen_NN for_IN the_DT detection_NN of_IN antibodies_NNS in_IN CSF_NP of_IN patients_NNS with_IN tuberculous_JJ meningitis_NN could_MD clearly_RB differentiate_VB the_DT patient_JJ group_NN from_IN the_DT control_NN group_NN in_IN studies_NNS with_IN a_DT European_JJ population_NN ,_, but_CC no_DT such_JJ differentiation_NN was_VBD observed_VBN in_IN the_DT study_NN with_IN an_DT Indian_JJ population_NN ._SENT The_DT modified_JJ antibody_NN assay_NN mentioned_VBN here_RB has_VBZ a_DT fairly_RB good_JJ sensitivity_NN of_IN 73_CD %_NN for_IN patients_NNS with_IN tuberculous_JJ meningitis_NN and_CC a_DT specificity_NN of_IN 88_CD %_NN ,_, and_CC above_IN all_DT ,_, it_PP could_MD differentiate_VB between_IN the_DT patient_JJ group_NN and_CC control_NN group_NN in_IN the_DT Indian_JJ population_NN ._SENT In_IN Western_JJ countries_NNS ,_, the_DT prevalence_NN of_IN tuberculosis_NN is_VBZ low_JJ and_CC a_DT clear_JJ distinction_NN between_IN patient_NN and_CC control_NN populations_NNS is_VBZ possible_JJ ._SENT An_DT ELISA_NP with_IN the_DT 38-kDa_JJ antigen_NN specific_JJ for_IN the_DT M._NP tuberculosis_NN complex_NN showed_VBD a_DT sensitivity_NN of_IN 83_CD %_NN and_CC a_DT specificity_NN of_IN 99_CD %_NN ._SENT In_IN a_DT study_NN with_IN a_DT Chinese_JJ population_NN ,_, however_RB ,_, the_DT sensitivity_NN of_IN detection_NN of_IN IgG_NP antibodies_NNS to_TO the_DT 38-kDa_JJ antigen_NN was_VBD 64_CD %_NN and_CC the_DT specificity_NN was_VBD 81_CD %_NN ._SENT Similarly_RB ,_, an_DT ELISA_NP performed_VBD with_IN the_DT Ag5_NP antigen_NN to_TO study_VB the_DT antibody_NN response_NN in_IN patients_NNS with_IN pulmonary_JJ tuberculosis_NN showed_VBD a_DT sensitivity_NN of_IN 84_CD %_NN and_CC a_DT specificity_NN of_IN 96_CD %_NN for_IN populations_NNS in_IN low-prevalence_NN areas_NNS ,_, while_IN the_DT sensitivity_NN was_VBD 94_CD %_NN and_CC the_DT specificity_NN was_VBD 80_CD %_NN for_IN populations_NNS in_IN high-prevalence_NN areas_NNS ._SENT The_DT same_JJ ELISA_NP for_IN the_DT detection_NN of_IN antibodies_NNS used_VBN elsewhere_RB showed_VBD sensitivities_NNS that_WDT varied_VBD from_IN 49_CD to_TO 89_CD %_NN and_CC specificities_NNS that_WDT ranged_VBD from_IN 88_CD to_TO 98_CD %_NN ._SENT The_DT A60_NP antigen_NN ,_, which_WDT is_VBZ a_DT thermostable_JJ component_NN of_IN the_DT purified_VBN protein_NN derivative_NN ,_, has_VBZ been_VBN used_VBN in_IN the_DT serodiagnosis_NN of_IN tuberculosis_NN ._SENT In_IN patients_NNS with_IN smear-negative_JJ but_CC culture-positive_JJ pulmonary_JJ tuberculosis_NN ,_, measurement_NN of_IN both_DT IgM_NP and_CC IgG_NP by_IN ELISA_NP revealed_VBD a_DT sensitivity_NN of_IN 68_CD %_NN and_CC a_DT specificity_NN of_IN 100_CD %_NN ._SENT In_IN the_DT pediatric_JJ group_NN ,_, at_IN a_DT chosen_VBN specificity_NN of_IN 98_CD %_NN ,_, anti-A60_NP IgG_NP antibodies_NNS were_VBD observed_VBN in_IN 68_CD %_NN of_IN children_NNS with_IN clinically_RB active_JJ tuberculosis_NN ._SENT In_IN the_DT Indian_JJ population_NN ,_, an_DT ELISA_NP with_IN the_DT A60_NP antigen_NN for_IN the_DT detection_NN of_IN IgM_NP antibodies_NNS in_IN patients_NNS with_IN pulmonary_JJ tuberculosis_NN had_VBD a_DT sensitivity_NN of_IN 77.5_CD %_NN and_CC a_DT specificity_NN of_IN 87.5_CD %_NN ,_, while_IN quantification_NN of_IN antibodies_NNS in_IN patients_NNS with_IN neurotuberculosis_NN showed_VBD a_DT sensitivity_NN of_IN 63_CD %_NN and_CC a_DT specificity_NN of_IN 100_CD %_NN ._SENT When_WRB titers_NNS of_IN antibodies_NNS to_TO the_DT 19-kDa_NP antigen_NN in_IN the_DT Indian_JJ population_NN were_VBD measured_VBN by_IN ELISA_NP ,_, the_DT test_NN was_VBD found_VBN to_TO have_VB a_DT poor_JJ sensitivity_NN (_( 8_CD %_NN )_) ,_, but_CC the_DT same_JJ test_NN used_VBN for_IN a_DT population_NN in_IN the_DT United_NP Kingdom_NP was_VBD found_VBN to_TO have_VB a_DT sensitivity_NN of_IN 58_CD %_NN and_CC a_DT specificity_NN of_IN 97_CD %_NN ._SENT An_DT ELISA_NP for_IN the_DT detection_NN of_IN antilipoarabinomannan_JJ antibodies_NNS in_IN sera_NN from_IN patients_NNS with_IN pulmonary_JJ ,_, miliary_JJ ,_, and_CC pleural_JJ tuberculosis_NN and_CC pleural_JJ lymphadenitis_NN and_CC in_IN CSF_NP from_IN patients_NNS with_IN tuberculous_JJ meningitis_NN had_VBD an_DT overall_JJ sensitivity_NN of_IN 61_CD to_TO 72_CD %_NN and_CC a_DT specificity_NN of_IN 72_CD %_NN ._SENT Among_IN the_DT HIV-negative_JJ patients_NNS with_IN active_JJ tuberculosis_NN ,_, the_DT sensitivity_NN of_IN antilipoarabinomannan_NP antibody_NN detection_NN ranged_VBD from_IN 21.5_CD to_TO 89_CD %_NN ,_, but_CC the_DT sensitivity_NN of_IN detection_NN was_VBD generally_RB poor_JJ ,_, about_RB 7_CD to_TO 40_CD %_NN ,_, for_IN HIV-positive_JJ patients_NNS ._SENT In_IN developing_VBG countries_NNS like_IN India_NP ,_, where_WRB the_DT prevalence_NN of_IN tuberculosis_NN is_VBZ high_JJ and_CC where_WRB individuals_NNS are_VBP by_IN and_CC large_JJ vaccinated_VBN with_IN BCG_NP or_CC exposed_VBN to_TO environmental_JJ mycobacteria_NNS ,_, antibodies_NNS are_VBP present_JJ even_RB in_IN the_DT healthy_JJ control_NN population_NN ,_, so_RB that_IN the_DT cutoff_NN for_IN any_DT diagnostic_JJ test_NN is_VBZ high_JJ ._SENT The_DT antibody_NN test_NN with_IN partially_RB purified_VBN antigen_NN developed_VBN in_IN the_DT study_NN described_VBD here_RB shows_VBZ a_DT sensitivity_NN of_IN 80_CD %_NN and_CC a_DT specificity_NN of_IN 90_CD %_NN for_IN patients_NNS with_IN pulmonary_JJ tuberculosis_NN ._SENT These_DT results_NNS are_VBP quite_RB acceptable_JJ and_CC compare_VB well_RB with_IN those_DT of_IN tests_NNS from_IN Western_JJ countries_NNS ._SENT Previous_JJ reports_NNS have_VBP indicated_VBN that_IN ELISA_NP kits_NNS for_IN the_DT detection_NN of_IN antibody_NN for_IN the_DT diagnosis_NN of_IN tuberculosis_NN have_VBP poor_JJ sensitivities_NNS and_CC specificities_NNS ._SENT Clinical_JJ evaluation_NN of_IN the_DT Andelisa_NP IgG_NP kit_NN ,_, which_WDT uses_VBZ the_DT A60_NP antigen_NN derived_VBN from_IN M._NP bovis_NP BCG_NP ,_, gave_VBD a_DT sensitivity_NN of_IN 48.3_CD %_NN and_CC a_DT specificity_NN of_IN 92_CD %_NN ,_, while_IN the_DT Kreatech_NP IgA_NP kit_NN ,_, which_WDT uses_VBZ the_DT KP90_NP antigen_NN derived_VBN from_IN M._NP tuberculosis_NN ,_, showed_VBD a_DT sensitivity_NN of_IN 49.7_CD %_NN and_CC a_DT specificity_NN of_IN 84_CD %_NN ._SENT Simultaneous_JJ evaluation_NN of_IN seven_CD serological_JJ tests_NNS ,_, i.e._FW ,_, two_CD ICTs_NNS and_CC five_CD ELISAs_NNS ,_, with_IN the_DT same_JJ clinical_JJ samples_NNS also_RB showed_VBD poor_JJ to_TO modest_JJ sensitivities_NNS that_WDT ranged_VBD from_IN 16_CD to_TO 57_CD %_NN ._SENT The_DT specificities_NNS of_IN these_DT tests_NNS ranged_VBN from_IN 80_CD to_TO 97_CD %_NN with_IN sera_NN from_IN the_DT Mantoux_NP test_NN controls_NNS and_CC 62_CD to_TO 100_CD %_NN with_IN sera_NN from_IN the_DT anonymous_JJ controls_NNS ._SENT These_DT results_NNS show_VBP lower_JJR sensitivities_NNS and_CC specificities_NNS ,_, indicating_VBG considerable_JJ overlap_VBP in_IN antibody_NN levels_NNS in_IN the_DT healthy_JJ control_NN group_NN and_CC the_DT patient_JJ group_NN and_CC indicating_VBG that_DT none_NN of_IN the_DT tests_NNS has_VBZ utility_NN for_IN the_DT diagnosis_NN of_IN tuberculosis_NN ._SENT Evaluation_NN of_IN the_DT validity_NN of_IN the_DT ICT_JJ kit_NN in_IN a_DT study_NN with_IN a_DT Korean_JJ population_NN showed_VBD a_DT sensitivity_NN of_IN 73_CD %_NN for_IN patients_NNS with_IN fresh_JJ cases_NNS of_IN tuberculosis_NN and_CC 87_CD %_NN for_IN patients_NNS with_IN reactivated_VBN tuberculosis_NN ,_, while_IN the_DT specificity_NN was_VBD 88_CD %_NN for_IN the_DT healthy_JJ group_NN and_CC 94_CD %_NN for_IN the_DT nontuberculous_JJ patients_NNS and_CC hospital_NN workers_NNS ._SENT A_DT similar_JJ evaluation_NN of_IN the_DT ICT_JJ kit_NN in_IN Madagascar_NP showed_VBD sensitivities_NNS of_IN 68.2_CD %_NN for_IN patients_NNS with_IN pulmonary_JJ tuberculosis_NN and_CC 65.2_CD %_NN for_IN patients_NNS with_IN extrapulmonary_JJ tuberculosis_NN and_CC a_DT specificity_NN of_IN 83.3_CD %_NN ._SENT However_RB ,_, evaluation_NN of_IN the_DT ICT_JJ kit_NN with_IN the_DT Indian_JJ population_NN showed_VBD an_DT overall_JJ sensitivity_NN of_IN 20_CD %_NN for_IN patients_NNS in_IN the_DT first_JJ month_NN of_IN the_DT disease_NN (_( fresh_JJ cases_NNS )_) and_CC a_DT very_RB low_JJ sensitivity_NN of_IN 4_CD %_NN ._SENT The_DT test_NN was_VBD also_RB positive_JJ for_IN 30_CD %_NN of_IN cases_NNS of_IN disease_NN caused_VBN by_IN mycobacteria_NNS other_JJ than_IN M._NP tuberculosis_NN ,_, indicating_VBG cross-reactivity_NN ._SENT The_DT overall_JJ specificity_NN of_IN the_DT test_NN was_VBD 89_CD %_NN ._SENT The_DT ELISA_NP kit_NN for_IN the_DT detection_NN of_IN IgG_NP antibodies_NNS against_IN tuberculous_JJ glycolipid_JJ antigen_NN containing_VBG cord_NN factor_NN (_( TBGL_NP Ag_NP )_) had_VBD a_DT sensitivity_NN of_IN 87_CD %_NN and_CC a_DT specificity_NN of_IN 100_CD %_NN ._SENT The_DT other_JJ findings_NNS included_VBN in_IN the_DT report_NN were_VBD an_DT increase_NN in_IN the_DT antibody_NN titers_NNS after_IN the_DT start_NN of_IN antituberculosis_NN chemotherapy_NN and_CC the_DT persistence_NN of_IN antibodies_NNS in_IN the_DT circulation_NN even_RB after_IN the_DT completion_NN of_IN treatment_NN ._SENT The_DT ICT_JJ kit_NN developed_VBN for_IN detection_NN of_IN antibodies_NNS against_IN the_DT 38-kDa_JJ antigen_NN of_IN M._NP tuberculosis_NN had_VBD an_DT overall_JJ sensitivity_NN of_IN 70_CD to_TO 92_CD %_NN and_CC an_DT overall_JJ specificity_NN of_IN 92_CD to_TO 93_CD %_NN for_IN patients_NNS with_IN pulmonary_JJ tuberculosis_NN ._SENT For_IN patients_NNS with_IN extrapulmonary_JJ tuberculosis_NN ,_, the_DT overall_JJ sensitivity_NN was_VBD 76_CD %_NN and_CC the_DT overall_JJ specificity_NN was_VBD 92_CD %_NN ._SENT Results_NNS from_IN a_DT study_NN conducted_VBN in_IN the_DT Europe_NP demonstrated_VBD a_DT low_JJ sensitivity_NN of_IN 50_CD %_NN but_CC a_DT high_JJ specificity_NN of_IN 100_CD %_NN ._SENT This_DT low_JJ sensitivity_NN will_MD result_VB in_IN many_JJ false-negative_JJ results_NNS ,_, whereby_WRB the_DT negative_JJ predictive_JJ value_NN will_MD be_VB unacceptably_RB low_JJ even_RB in_IN countries_NNS with_IN a_DT high_JJ prevalence_NN of_IN tuberculosis_NN ._SENT A_DT specificity_NN of_IN 100_CD %_NN is_VBZ not_RB possible_JJ in_IN developing_VBG countries_NNS ,_, particularly_RB in_IN tropical_JJ areas_NNS where_WRB people_NNS are_VBP permanently_RB in_IN contact_NN with_IN various_JJ pathogens_NNS and_CC develop_VB cross-reacting_NN antibodies_NNS ,_, resulting_VBG in_IN poor_JJ test_NN specificities_NNS ._SENT Hence_RB ,_, every_DT new_JJ serodiagnostic_JJ test_NN should_MD be_VB validated_VBN with_IN controls_NNS from_IN countries_NNS where_WRB the_DT test_NN would_MD be_VB applied_VBN ._SENT In_IN this_DT context_NN a_DT cutoff_NN of_IN 100_CD was_VBD determined_VBN on_IN the_DT basis_NN of_IN the_DT values_NNS obtained_VBN for_IN the_DT control_NN population_NN ,_, which_WDT included_VBD contacts_NNS and_CC patients_NNS with_IN nontubercular_JJ disease_NN ._SENT It_PP was_VBD observed_VBN ,_, however_RB ,_, that_IN if_IN the_DT cutoff_NN were_VBD raised_VBN to_TO 125_CD ,_, the_DT specificity_NN would_MD go_VB up_RP to_TO 97_CD %_NN and_CC the_DT sensitivities_NNS would_MD be_VB 69.7_CD ,_, 66.6_CD ,_, and_CC 51.6_CD %_NN ,_, for_IN groups_NNS I_PP to_TO III_NP ,_, respectively_RB ,_, as_IN shown_VBN in_IN Table_NP ,_, with_IN a_DT positive_JJ predictive_JJ value_NN of_IN 94_CD %_NN ._SENT Thus_RB ,_, it_PP is_VBZ possible_JJ to_TO alter_VB the_DT cutoff_NN and_CC obtain_VB appropriate_JJ sensitivity_NN ,_, specificity_NN ,_, and_CC predictive_JJ values_NNS according_VBG to_TO the_DT prevalence_NN of_IN the_DT disease_NN in_IN different_JJ areas_NNS ._SENT The_DT antibody_NN test_NN kit_NN described_VBD here_RB involves_VBZ very_RB few_JJ steps_NNS in_IN terms_NNS of_IN the_DT addition_NN of_IN reagents_NNS and_CC a_DT shorter_JJR incubation_NN time_NN ,_, which_WDT make_VBP it_PP user_NN friendly_JJ ._SENT Above_IN all_DT it_PP has_VBZ a_DT good_JJ sensitivity_NN and_CC a_DT good_JJ specificity_NN ._SENT This_DT kit_NN should_MD benefit_VB the_DT population_NN by_IN providing_VBG diagnoses_NNS early_JJ in_IN the_DT course_NN of_IN disease_NN and_CC ,_, hence_RB ,_, permitting_VBG the_DT early_JJ administration_NN of_IN appropriate_JJ chemotherapy_NN ._SENT 